Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events

References

• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121:569–583.
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J, et al.; American College of Chest Physicians. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):199S–233S.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076.
   PubMed Web of Science ®Google Scholar
• Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2:637–643.
   PubMedGoogle Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235.
   PubMedGoogle Scholar
• Schrör K, Rauch BH. Aspirin and lipid mediators in the cardiovascular system. Prostaglandins Other Lipid Mediat. 2015;121:17–23.
   PubMed Web of Science ®Google Scholar
• Dai S-X, Li W-X, Li G-H, et al. Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin. Peer J. 2016 Mar 10;4:e1791.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250:154–161.
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007;109:2285–2292.
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141–152.
   PubMed Web of Science ®Google Scholar
• Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99:7634–7639.
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542–547.
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272–277.
   PubMed Web of Science ®Google Scholar
• Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840–845.
   PubMed Web of Science ®Google Scholar
• Mehta JL, Mehta P, Lopez L, et al. Platelet function and biosynthesis of prostacyclin and thromboxane A2 in whole blood after aspirin administration in human subjects. J Am Coll Cardiol. 1984;44:806–811.
   Google Scholar
• Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800–805.
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.
   PubMed Web of Science ®Google Scholar
• Antonino MJ, Coppolecchia R, Mahla E, et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. Thromb Res. 2010;126:384–385.
   PubMed Web of Science ®Google Scholar
• Faraday N, Becker DM, Yanek LR, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol. 2006;98:774–779.
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–1708.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation. 2007;115:3156–3164.
   PubMed Web of Science ®Google Scholar
• DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56:3014–3019.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118:1705–1712.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655.
   PubMed Web of Science ®Google Scholar
• Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011;105:336–344.
   PubMed Web of Science ®Google Scholar
• Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006;95:652–658.
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol. 2011;150:39–44.
   PubMed Web of Science ®Google Scholar
• Würtz M, Hvas A-M, Jensen LO, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol. 2014;175:274–279.
   PubMed Web of Science ®Google Scholar
• Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220–1230.
   PubMed Web of Science ®Google Scholar
• Christensen KH, Grove EL, Würtz M, et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2015;26:230–235.
   PubMed Web of Science ®Google Scholar
• Bonten TN, Saris A, van Oostrom MJ, et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost. 2014;112:1209–1218.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4:180–187.
   PubMed Web of Science ®Google Scholar
• Dillinger J-G, Drissa A, Sideris G, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164:600–606.
   PubMed Web of Science ®Google Scholar
• Spectre G, Arnetz L, Östenson C-G, et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106:491–499.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Chaudhary R, et al. Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. Am J Cardiol. 2016 Sep 20. pii: S0002-9149(16)31504-1.
   Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379–386.
   PubMed Web of Science ®Google Scholar
• Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012;164:153–162.
   PubMed Web of Science ®Google Scholar
• Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018–2024.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–1243.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother. 2010;11:2251–2259.
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556–1565.
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65–77.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–1199.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Montalescot G, van’t Hof AW, Lapostolle F, et al.; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–1027.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–219.
   PubMed Web of Science ®Google Scholar
• Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11:1867–1876.
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–877.
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17:164–172.
   PubMed Web of Science ®Google Scholar
• Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61:723–727.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Moulias A, Koutsogiannis N, et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv. 2013;6:277–283.
   PubMed Web of Science ®Google Scholar
• Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078–2085.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost. 2010;104:609–617.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, et al.; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2011;124:544–554.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (switching anti platelet-2). J Am Coll Cardiol. 2014;63:1500–1509.
   PubMed Web of Science ®Google Scholar
• Bhavaraju K, Georgakis A, Jin J, et al. Antagonism of P2Y12 reduces physiological thromboxane levels. Platelets. 2010;21:604–609.
   PubMed Web of Science ®Google Scholar
• Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem. 1999;274:29108–29114.
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Leadbeater PD, Chan MV, et al. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011;9:2103–2105.
   PubMed Web of Science ®Google Scholar
• Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72:619–633.
   PubMed Web of Science ®Google Scholar
• Grześk G, Kozinski M, Tantry US, et al. High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. Biomed Res Int. 2013;2013:928271.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Roe MT, Ohman EM, et al. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study. Am Heart J. 2016;174:120–128.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al.; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. Engl J Med. 2016 May 10;375:35–43. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Nijjer SS, Davies JE, Francis DP. Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON TIMI-38 and PLATO. Int J Cardiol. 2012;158:181–185.
   PubMed Web of Science ®Google Scholar
• Biscaglia S, Campo G, Pavasini R, et al. Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets. 2016;27:484–487.
   PubMed Web of Science ®Google Scholar
• Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65:511–512.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Barampoutis N, Gkizas V, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet. 2016;55:359–367.
   PubMed Web of Science ®Google Scholar